Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Christen Mowad MD
Christen Maria Mowad MD Advisory Board
Robert Brodell MD, FAAD
Robert T. Brodell MD, FAAD Editor-in-Chief
Sarah Chamlin MD
Sarah L. Chamlin MD Advisory Board
See All Experts
featured
Published in Dermatology

Expert Opinion / Interview · August 08, 2013

Immunotherapy in Melanoma

Michael Postow MD

 

 Save  Recommend
 Share

Additional Info

  1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443-2454.

  2. Sznol M, Kluger HM, Hodi FS, et al. Survival and long-term follow-up of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538). Paper presented at: American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, Illinois. J Clin Oncol. 2013(suppl; abstr CRA9006).

  3. Hodi SF, Lee SJ, McDermott DF, et al. Multicenter, randomized phase II trial of Gm-CSf (GM) and ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol. 2013(suppl; abstr CRA9007).

  4. Wolchok JD, Kluger HM, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.

  5. Wolchok JD, Kluger HM, Callahan MK, et al. Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL). Paper presented at: American Society of Clinical Oncology; May 31-June 4, 2013; Chicago, Illinois. J Clin Oncol. 2013(suppl; abstr 9012).

  6. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-1231.

  7. Comin-Anduix B, Chodon T, Sazegar H, et al. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations. Clin Cancer Res. 2010;16(24):6040-6048.

  8. Ribas A, Hodi SF, Callahan C, et al. Hepatotoxicity with Combination of Vemurafenib and Ipilimumab [correspondence].N Engl J Med 2013;368(14):1365-1366.

  9. Phase I study of the BRAF inhibitor dabrafenib +/− MEK inhibitor trametinib in combination with ipilimumab for V600E/K mutation positive metastatic or unresectable melanoma. NCT01767454. http://clinicaltrials.gov/ct2/show/NCT01767454?term=dabrafenib+and+ipilimumab&rank=1. Accessed July 14, 2013.

Further Reading

Most Read This Week

Recently Updated